MPMarina Yu. Pomazanova

Marina Yu. Pomazanova

*This is an algorithmically generated author record based on publicly available information.

Marina Yu. Pomazanova has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diseases of cardiovascular system in patients with moderate-to-severe and severe forms of psoriasis

    by A. A. Hotko, M. Yu. Pomazanova, M. V. Durleshter

    Psoriasis is one of the most common chronic immune-mediated skin diseases. One of the widely discussed gastroenterological comorbidities of psoriasis is chronic inflammatory diseases of the gastrointestinal tract. The article presents the results of the analysis of the case histories of patients with moderate-to-severe and severe forms of psoriasis and concomitant pathology – inflammatory bowel diseases (Clinical Dermatovenerologic Dispensary, Krasnodar, Russia). The analysis of 16 case histories of patients with moderate-to-severe and severe psoriasis has been carried out, where one can see the clinical and practical significance of the combined pathology – psoriasis and inflammatory bowel diseases. From the analysis, one can conclude that there is a direct relationship between the severity of the course of the skin pathological process and the development of intestinal diseases, as well as the influence of ustekinumab on the course of combined pathology – psoriasis, ulcerative colitis and Crohn’s disease.

  • Diseases of cardiovascular system in patients with severe and moderatesevere forms of psoriasis

    by A. A. Hotko, M. Yu. Pomazanova, Y. V. Kozyr

    Psoriasis is one of the most common chronic recurrent dermatoses, which is not limited to skin lesions, leading to a violation of the functions of various body organ systems. The article presents the results of the analysis of the medical histories of patients of Clinical dermatovenerologic dispensary (Krasnodar Region of Russia) with moderate-severe and severe forms of psoriasis and concomitant cardiological pathology. The article presents data from 70 case histories of patients with moderate to severe psoriasis, the analysis of which shows the clinical and practical significance of comorbidity of psoriasis. From the analysis, we conclude that there is a direct relationship between the severity of the course of the cutaneous pathological process and the aggravation of the cardiological diagnosis. The higher the severity of psoriasis, the higher the risk of developing acute coronary syndrome, myocardial infarction and other cardiac pathology.


  • Certolizumab pegol in treatment of psoriasis and psoriatic arthritis: patient profiles, inspection, monitoring of safety

    by A. A. Khotko, M. Yu. Pomazanova, Ya. V. Kozyr

    Цертолизумаба пэгол в лечении псориаза и псориатического артрита. Профиль пациента, обследование, мониторинг эффективности и переносимости

  • Open Access

    Multimorbidity in Pediatric Dermatology: Clinical Case

    by Nikolay N. Murashkin, Alexander I. Materikin, Eduard T. Ambarchian, Roman V. Epishev, Leonid A. Opryatin, Roman A. Ivanov, Daria S. Kukoleva, Daria G. Kuptsova, Alexander A. Pushkov, Marina Yu. Pomazanova, et al.

    Background. Nowadays, dermatoses with mixed clinical picture and resistant to classical management become more common. The presence of various genetic disorders typical for most chronic dermatoses may indicate possible combination of several nosologies.Clinical Case Description. The article presents the clinical case of multimorbid condition in 10 years old patient who has nucleotide variants in CARD14 and EXPH5 genes. Mutations in CARD14 gene are typical for patients with type 2 psoriasis and pityriasis rubra pilaris (autosomal dominant type), while mutations in EXPH5 gene are typical for patients with non-specific epidermolysis bullosa (autosomal recessive type). Mutation in the TGM1 gene that is described in patients with congenital ichthyosis (autosomal recessive type), pathogenic mutations in KRT74 gene typical for ectodermal dysplasia, hypotrichosis and uncombable hair syndrome, and mutations in the KRT86 gene typical for monilethrix were also revealed. Medical history taking and histological examination as well as clinical data evaluating are crucial for correct diagnosis. They allow to understand the absence of the such manifestations in relatives and reveal various pathological processes in the epidermis. Molecular genetic testing with new generation sequencing (NGS) helps to finally establish the diagnosis and determine the further tactics for patient management.Conclusion. Multidisciplinary approach and use of high-technology methods of examination and treatment (such as molecular genetic testing and biological therapy) are required for final diagnosis in severe forms of chronic dermatosis resistant to treatment and for decision on correct tactics for the further management of such patients.

  • Open Access

    Psoriasis Comorbidities in Childhood

    by Nikolay N. Murashkin, Larisa S. Kruglova, Iuliia A. Kovalenko, Eduard T. Ambarchian, Roman V. Epishev, Alexander I. Materikin, Leonid A. Opryatin, Roman A. Ivanov, Daria S. Kukoleva, Daria G. Kuptsova, et al.

    Psoriasis is multifactorial systemic disease characterized by excessive hyperkeratosis due to impaired keratinocytes proliferation and differentiation. This disease often manifests in childhood and it is usually associated with the development of comorbid conditions some of which are combined by the term «psoriatic march» (obesity, metabolic syndrome, etc.). The course of psoriasis and related comorbidities in children has several specific features that determine topicality of studying all the aspects of clinical diagnosis and prevention in childhood. The article summarizes recent ideas on the prevalence, pathogenesis features and early diagnosis of comorbid diseases in children with psoriasis.


  • Open Access

    Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study

    by Nikolay N. Murashkin, Eduard T. Ambarchian, Roman V. Epishev, Alexander I. Materikin, Leonid A. Opryatin, Roman A. Ivanov, Daria S. Kukoleva, Marina Y. Pomazanova, Daria G. Kuptsova, Yana V. Kozyr, et al.

    Background. The study of psoriasis biological therapy aspects in children has certain topicality due to the small number and disunity of individual observations and the lack of special registers for pediatric patients.Objective. Our aim was to study ustekinumab efficacy and safety in children with plaque (PP), erythrodermic (EP) and palmoplanar (PPP) forms of psoriasis.Methods. The analysis of ustekinumab efficacy and safety has been carrying out for 1 year. The evaluation of therapy efficacy was based on definition of improvement of PASI scores (PASI 75, PASI 90 and PASI 100) on the 16th, 28th, 40th and 52nd weeks of follow-up and children's dermatology life quality index (CDLQI). Ustekinumab therapy safety analysis was based on registration and evaluation of adverse effects. Results. The study included 67 children with PP, EP and PPP aged 12 to 18 years. PP group results: the PASI 75 response at the 52nd week of therapy was observed in 35 children (100%), PASI 90 — in 33 (94%), PASI 100 — in 30 (86%). EP group results: 10 patients (56%) have reached PASI 75 on the 16th week, while none of patients have improved to PASI 90 and PASI 100 scores. The PASI 75 response at the 52nd week of therapy was observed in 18 children (100%), PASI 90 — in 17 (94%), PASI 100 — in 7 (39%). Only 1 patient (7%) with PPP has showed the score decrease to PASI 75 on the 16th week. Adverse effects were reported in 2 patients.Conclusion. Ustekinumab is the effective and safe treatment for moderate and severe forms of PP and EP in children, and it can also be considered as one of the alternative methods for PPP treatment in pediatrics.


  • Open Access

    Psoriasis and Psoriatic Arthritis in ChildhoodPsoriasis and Psoriatic Arthritis in Childhood

    by Nikolay N. Murashkin, Alexander I. Materikin, Eduard T. Ambarchian, Roman V. Epishev, Leonid A. Opryatin, Roman A. Ivanov, Daria S. Kukoleva, Daria G. Kuptsova, Marina U. Pomazanova

    Psoriasis is chronic inflammatory skin disease that can develop at any age. Approximately 20–30% of all patients report about first rashes before the age of 18. Psoriatic arthritis is one of psoriasis comorbid conditions. Its signs can range from mild to extremely severe destructive forms. Arthralgia, joint stiffness and swelling are the most common symptoms. Early psoriatic arthritis treatment onset allows to control joint damage which usually occurs during the first 2 years of the disease. The moderate and severe course of psoriasis and psoriatic arthritis may require systemic therapy, however, there is not much data on the efficacy and toxicity of systemic agents in the pediatric practice. This article provides the review of studies on etanercept efficacy and safety in children with psoriatic arthritis.


  • Open Access

    Targeted therapy of psoriasis: inhibition of the IL-23 signaling pathway — evidence from clinical studies and real practice

    by Alkes A. Hotko, Marina Yu. Pomazanova, Larisa Kruglova

    The article presents the results of clinical studies of the efficacy and safety of the use of a new drug of genetically engineered biological therapy guselkumab. Guselkumab is the first representative of the interleukin-23 (IL-23) inhibitor class and has a number of advantages over existing therapy. According to direct comparative randomized clinical trials, guselkumab is superior in the short-term and, most importantly, in the long-term to most genetically engineered biologic drugs, including TNF- inhibitors, secukinumab and ustekinumab. In phase 3 studies (VOYAGE 1 and VOYAGE 2), the ECLIPSE study shows that guselkumab can achieve complete (PASI 100) and almost complete (PASI 90) skin cleansing by 16 weeks from the start of therapy in 37.4 and 73.3% of patients, respectively, with a subsequent increase in the proportion of patients with clean and almost clean skin by 24 weeks to 44.4 and 80.2%, respectively, and maintaining the achieved performance indicators for 4 years at the level of 51.7 and 84.0% respectively. One of the potential advantages of IL-23 inhibitors is also the long-term maintenance of the achieved effect after treatment cessation. Guselkumab therapy is characterized by a favorable safety profile comparable to ustekinumab. During the follow-up period of patients in the course of randomized controlled trials of phase 3, data were obtained on the high safety of the drug and the absence of significant risks for serious infections, cardiovascular events, malignancies or suicidal tendencies. The drug is effective for insufficient response to adalimumab and ustekinumab. The article presents 3 clinical cases of guselkumab use in patients with severe, including "problematic" psoriasis, comorbid pathology, with inefficiency or intolerance to systemic therapy, with secondary inefficiency of adalimumab. All patients managed to achieve a PASI of 90/100. No adverse events were observed.